Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Purity:
95.00%
CAS Number:
[2101829-58-5]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted